

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
11 May 2006 (11.05.2006)

PCT

(10) International Publication Number
WO 2006/049454 A1(51) International Patent Classification:
A61K 31/7125 (2006.01)(21) International Application Number:
PCT/KR2005/003717(22) International Filing Date:
4 November 2005 (04.11.2005)

(25) Filing Language: Korean

(26) Publication Language: English

(30) Priority Data:
10-2004-0090000
5 November 2004 (05.11.2004) KR(71) Applicant (for all designated States except US): **BIO CLUE & SOLUTION CO., LTD** [KR/KR]; Dermato-Immunology Lab. #4003, Catholic Research Institute of Medical Science, Catholic University Medical College, 505 Banpo-dong, Seocho-gu, Seoul 137-040 (KR).

(71) Applicant and

(72) Inventor: **KIM, Tae-Yoon** [KR/KR]; Asia Seonsuchon Apt. #8-702, 86 Chamsil-dong, Songpa-gu, Seoul 138-220 (KR).

(71) Applicant and

(72) Inventor (for all designated States except US): **SHIN, Dong-Heon** [KR/KR]; Shindonga Apt. #3-1305, Seobingo-dong, Yongsan-gu, Seoul 140-751 (KR).


(72) Inventors; and

(75) Inventors/Applicants (for US only): **KIM, Doo-Sik** [KR/KR]; 84-3 Yeonhui 2-dong, Seodamun-gu, Seoul 120-824 (KR). **KWON, Hyung-Joo** [KR/KR]; Kunyoung Apt. #104-1506, Yongam-dong, Sangdang-gu, Cheongju, Chungcheongbuk-do 360-770 (KR). **KIM, Yang-Soon** [KR/KR]; 721-15 Banpo 1-dong, Seocho-gu, Seoul 137-809 (KR).(74) Agents: **KIM, Seog-Hyun** et al.; 9th Floor, Daekyung Building, 120, 2-ka, Taepyung-ro, Chung-ku, Seoul 100-724 (KR).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK,

[Continued on next page]

(54) Title: THERAPEUTIC USE OF CPG OLIGODEOXYNUCLEOTIDE FOR SKIN DISEASE



(57) Abstract: Disclosed is the therapeutic use of CpG oligodeoxynucleotides for skin diseases. The CpG oligodeoxynucleotides (CpG ODNs) of the present invention show excellent immunoactive effects against skin diseases in both cases of CpG ODNs with a phosphorothioate backbone and CpG ODNs with a phosphodiester backbone.

WO 2006/049454 A1



SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- with sequence listing part of description published separately in electronic form and available upon request from the International Bureau

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.